AbbVie has received US FDA approval for Emblaveo to be used in conjunction with metronidazole for individuals with cIAI.

The FDA has approved Emblaveo with metronidazole for patients with complicated intra-abdominal infections and limited options.

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...

The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...

Make your antibiotic medication as effective as possible by getting these answers before you leave the doctor's office or pharmacy.

AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...

Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be ...

AbbVie receives US FDA approval for Emblaveo to treat adults with complicated intra-abdominal infections with limited or no treatment options: North Chicago, Illinois Monday, Febr ...

Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.

Addresses the significant threat of antimicrobial resistance.

Expert Rev Anti Infect Ther. 2011;9(2):215-226. As with most mammalian bites, amoxicillin/clavulanic acid (augmentin) is a reasonable empiric antibiotic in an ...

POD in adults is usually treated with oral antibiotics; 250–500 mg doses of oral tetracycline ... can also speed resolution of POD. One percent metronidazole cream is effective when applied ...